✦ LIBER ✦

In Reference to Tacrolimus: A New Option in Therapy-Resistant Chronic External Otitis

✍ Scribed by Philipp P. Caffier; Heidemarie Haupt; Benedikt Sedlmaier; Wolfgang Harth

Book ID: 119770897
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 64 KB
Volume: 117
Category: Article
ISSN: 0023-852X
DOI: 10.1097/mlg.0b013e31811436bd

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

In Reference to Tacrolimus: A New Option

In Reference to Tacrolimus: A New Option in Therapy-Resistant Chronic External Otitis

✍ Baran Acar; Hayriye Karabulut; Mehmet Ali Babademez; Murat Karaçsen 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

In reference to Tacrolimus: A new option

In reference to Tacrolimus: A new option in therapy-resistant chronic external otitis

✍ Paul Lennon; John Fenton 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

Tacrolimus: A New Option in Therapy-Resi

Tacrolimus: A New Option in Therapy-Resistant Chronic External Otitis

✍ Philipp P. Caffier; Wolfgang Harth; Babak Mayelzadeh; Heidemarie Haupt; Benedikt 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 515 KB

In response to Tacrolimus: A new option

In response to Tacrolimus: A new option in therapy-resistant chronic external otitis

✍ Philipp P. Caffier; Heidemarie Haupt; Benedikt Sedlmaier; Wolfgang Harth 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB

Anti-TNF alpha therapy in chronic necrot

Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis

✍ El-Shabrawi, Y; Hermann, J 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 98 KB

Matrix therapy in regenerative medicine,

Matrix therapy in regenerative medicine, a new approach to chronic wound healing

✍ V. Barbier-Chassefière; S. Garcia-Filipe; X. L. Yue; M. E. Kerros; E. Petit; P. 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 308 KB

## Abstract Nonhealing wounds remain a major health problem whose treatment is challenging and costly. Treatments based on cells or growth factors are still not very effective. We developed an entirely novel strategy consisting in treatment of the wound‐tissue matrix with biopolymers engineered to